Zurcher Kantonalbank (Zurich Cantonalbank) Gritstone Bio, Inc. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$32.8 Billion
Q3 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 30, 2024	SELL	$1.28 - $2.85 $5,719 - $12,733	-4,468 Reduced 90.3%	480 $0
Q3 2023 Oct 25, 2023	SELL	$1.19 - $2.26 $936 - $1,778	-787 Reduced 13.72%	4,948 $8,000
Q2 2023 Aug 07, 2023	SELL	$1.66 - $3.03 $2,873 - $5,244	-1,731 Reduced 23.19%	5,735 $11,000
Q1 2023 May 08, 2023	BUY	$2.13 - $3.74 $11,938 - $20,962	5,605 Added 301.18%	7,466 $20,000
Q4 2022 Feb 01, 2023	SELL	$2.17 - $3.92 $1,286 - $2,324	-593 Reduced 24.16%	1,861 $6,000
Q1 2022 Apr 21, 2022	BUY	$4.03 - $12.19 $9,889 - $29,914	2,454 New	2,454 $10,000

Others Institutions Holding GRTS

# of Institutions

Shares Held

35.4M

Call Options Held

395K

Put Options Held

132K

View Full List

About Gritstone bio, Inc.

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

More about GRTS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account